A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin

Status:
NOT_YET_RECRUITING

Trial end date:
2025-11-30

Target enrollment:

Participant gender:

PHASE3

Shandong University

Thrombopoietin